Maintenance therapy in non-small cell lung cancer

被引：21

作者：

Genestreti, Giovenzio ^{[1
]}

Di Battista, Monica ^{[1
]}

Cavallo, Giovanna ^{[1
]}

Bartolotti, Marco ^{[1
]}

Brandes, Alba A. ^{[1
]}

机构：

[1] IRCCS, Dept Med Oncol, Azienda USL, Inst Neurol Sci, Bologna, Italy

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2015年 / 15卷 / 07期

关键词：

advanced non-small cell lung cancer; lung cancer; maintenance therapy; Phase III randomized trial; review; QUALITY-OF-LIFE; PHASE-III TRIAL; PLATINUM-BASED CHEMOTHERAPY; CLINICAL-PRACTICE GUIDELINES; PEMETREXED PLUS CISPLATIN; NORTON-SIMON HYPOTHESIS; DOUBLE-BLIND; COST-EFFECTIVENESS; STAGE-IIIB; RANDOMIZED-TRIAL;

D O I：

10.1586/14737140.2015.1052410

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Several randomized trials have investigated the role of maintenance treatment for patients with advanced non-small cell lung cancer (NSCLC) not progressed after completion of first-line chemotherapy, with good performance score (PS) and no persistent chemotherapy-induced toxicity. Two separate strategies have been developed: the immediate use of non-cross-resistant drug (switch maintenance or early second-line therapy) or the continuation of platinum partner alone (continuation maintenance) or in combination with other drug (combination maintenance). Here we discuss how the benefits demonstrated in these studies may change clinical practice (in terms of potential toxicity and costs) and reflect on factors that may identify subgroups of patients who might benefit from maintenance therapy in general, and which maintenance therapy specifically.

引用

页码：839 / 846

页数：8

共 45 条

[21] An Empiric Estimate of the Value of Life: Updating the Renal Dialysis Cost-Effectiveness Standard [J].

Lee, Chris P. ;

Chertow, Glenn M. ;

Zenios, Stefanos A. .

VALUE IN HEALTH, 2009, 12 (01) :80-87

[22] Cost-Effectiveness of Maintenance Pemetrexed in Patients with Advanced Nonsquamous-Cell Lung Cancer from the Perspective of the Swiss Health Care System [J].

Matter-Walstra, Klazien ;

Joerger, Markus ;

Kuehnel, Ursula ;

Szucs, Thomas ;

Pestalozzi, Bernhard ;

Schwenkglenks, Matthias .

VALUE IN HEALTH, 2012, 15 (01) :65-71

[23]

NORTON L, 1986, CANCER TREAT REP, V70, P163

[24]

NORTON L, 1977, CANCER TREAT REP, V61, P1307

[25] A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer [J].

Nuijten, Mark J. C. ;

de Castro Carpeno, Javier ;

Chouaid, Christos ;

Vergnenegre, Alain ;

Grossi, Francesco ;

Bischoff, Helge ;

Heigener, David ;

Walzer, Stefan .

LUNG CANCER, 2012, 76 (03) :465-471

[26] Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small-cell lung cancer [J].

Park, Joon Oh ;

Kim, Sang-We ;

Ahn, Jin Seok ;

Suh, Cheolwon ;

Lee, Jung Shin ;

Jang, Joung Soon ;

Cho, Eun Kyung ;

Yang, Sung Hyun ;

Choi, Jin-Hyuk ;

Heo, Dae Seog ;

Park, Suk Young ;

Shin, Sang Won ;

Ahn, Myung Ju ;

Lee, Jong Seok ;

Yun, Young Ho ;

Lee, Jae-Won ;

Park, Keunchil .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) :5233-5239

[27] PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer [J].

Patel, Jyoti D. ;

Socinski, Mark A. ;

Garon, Edward B. ;

Reynolds, Craig H. ;

Spigel, David R. ;

Olsen, Mark R. ;

Hermann, Robert C. ;

Jotte, Robert M. ;

Beck, Thaddeus ;

Richards, Donald A. ;

Guba, Susan C. ;

Liu, Jingyi ;

Frimodt-Moller, Bente ;

John, William J. ;

Obasaju, Coleman K. ;

Pennella, Eduardo J. ;

Bonomi, Philip ;

Govindan, Ramaswamy .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (34) :4349-U77

[28] Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial [J].

Paz-Ares, Luis ;

de Marinis, Filippo ;

Dediu, Mircea ;

Thomas, Michael ;

Pujol, Jean-Louis ;

Bidoli, Paolo ;

Molinier, Olivier ;

Sahoo, Tarini Prasad ;

Laack, Eckart ;

Reck, Martin ;

Corral, Jesus ;

Melemed, Symantha ;

John, William ;

Chouaki, Nadia ;

Zimmermann, Annamaria H. ;

Visseren-Grul, Carla ;

Gridelli, Cesare .

LANCET ONCOLOGY, 2012, 13 (03) :247-255

[29] PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Paz-Ares, Luis G. ;

de Marinis, Filippo ;

Dediu, Mircea ;

Thomas, Michael ;

Pujol, Jean-Louis ;

Bidoli, Paolo ;

Molinier, Olivier ;

Sahoo, Tarini Prasad ;

Laack, Eckart ;

Reck, Martin ;

Corral, Jesus ;

Melemed, Symantha ;

John, William ;

Chouaki, Nadia ;

Zimmermann, Annamaria H. ;

Visseren-Grul, Carla ;

Gridelli, Cesare .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (23) :2895-+

[30] Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non-Small-Cell Lung Cancer [J].

Perol, Maurice ;

Chouaid, Christos ;

Perol, David ;

Barlesi, Fabrice ;

Gervais, Radj ;

Westeel, Virginie ;

Crequit, Jacky ;

Lena, Herve ;

Vergnenegre, Alain ;

Zalcman, Gerard ;

Monnet, Isabelle ;

Le Caer, Herve ;

Fournel, Pierre ;

Falchero, Lionel ;

Poudenx, Michel ;

Vaylet, Fabien ;

Segura-Ferlay, Celine ;

Devouassoux-Shisheboran, Mojgan ;

Taron, Miquel ;

Milleron, Bernard .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (28) :3516-3524

← 1 2 3 4 5 →